Melanoma News

CancerConnect melanoma news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of melanoma research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of melanoma treatment and survivorship.

Share

Melanoma News


Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings... Continue Reading

Melanoma Research Alliance Reports Wendy Selig to Step Down as President and CEO (February 9, 2015)

CancerConnect News:  The Melanoma Research Alliance (“MRA”) announced today that Wendy Selig has informed its Board of Directors of her plan to step down as President and CEO, posts she has held... Continue Reading

Yervoy® Improves Treatment of Stage III Melanoma (February 6, 2015)

CancerConnect News: The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with stage III melanoma appears promising, demonstrating an improvement by delaying cancer recurrence... Continue Reading

Coffee May Decrease Risk of Melanoma Skin Cancer (February 2, 2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been... Continue Reading

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is... Continue Reading

Final Budget Bill Doubles DoD Funding Available for Melanoma Research (December 11, 2014)

The Melanoma Research Alliance (MRA) hailed the inclusion in the omnibus appropriations bill providing government funding for Fiscal Year 2015 of $50 million in funding for the Department of Defense’s... Continue Reading

More Melanoma News

Latest Melanoma News By Stage


Screening/Prevention

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Melanoma Research Alliance Reports Wendy Selig to Step Down as President and CEO (February 9, 2015)

CancerConnect News:  The Melanoma Research Alliance (“MRA”) announced today that Wendy Selig has informed its Board of Directors of her plan to step down as President and CEO, posts she has held for the past five years, in order to establish a new... Continue Reading

Coffee May Decrease Risk of Melanoma Skin Cancer (February 2, 2015)

Coffee might do more than perk you up. New research suggests that coffee drinkers are less likely to develop malignant melanoma, and their risk decreases with every cup they drink.1 Coffee has long been associated with a reduction in the risk of various... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

More Screening and Prevention

Stages I-II

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

CancerConnect News:The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society of Melanoma Research (SMR)... Continue Reading

PV-10 Injection Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently reported. PV-10 is a 10% solution of Rose Bengal,... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to be more dangerous. Researchers in Australia wanted... Continue Reading

More Stages I-II

Stage III

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is... Continue Reading

Yervoy® Improves Treatment of Stage III Melanoma (February 6, 2015)

CancerConnect News: The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with stage III melanoma appears promising, demonstrating an improvement by delaying cancer recurrence and improving survival. Skin cancer is the most... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

More Stage III

Stage IV

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Keytruda® May Be More Effective than Yervoy® in Advanced Melanoma (April 20, 2015)

Keytruda® (pembrolizumab) appears to outperform Yervoy® (ipilimumab) at initial treatment of patients with advanced melanoma. Pharmaceutical company Merck announced these Phase III clinical trial findings in a press release in March 2015. Melanoma is... Continue Reading

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

More Stage IV

Recurrent

Melanoma Drug T-VEC Receives Recommendation for FDA Approval (May 1, 2015)

An advisory panel to the U.S. Food and Drug Administration (FDA) has recommended approval of the investigational drug T-VEC (talimogene laherparepvec) for the treatment of metastatic melanoma. Biopharmaceutical company Amgen recently announced plans to... Continue Reading

National Melanoma Awareness Month on CancerConnect (May 1, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of melanoma educational programs for national melanoma awareness month. As the month of May brings melanoma into focus, it’s time to increase public understanding... Continue Reading

Moffitt Researchers Discover Mechanism Leading to Drug Resistance, Metastasis in Melanoma Patients (January 9, 2015)

TAMPA, Fla. – Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve... Continue Reading

Melanoma Research News: Year in Review (January 7, 2015)

After several years of exciting developments in melanoma therapy, progress continued throughout 2014. Doctors specializing in the treatment of melanoma reported continued progress about optimizing the use of BRAF inhibitors and the long awaited PD-1 immunotherapy... Continue Reading

FDA Approves Nivolumab for Advanced Melanoma (December 23, 2014)

CancerConnect News: The FDA granted accelerated approval to nivolumab (Opdivo) for patients with unresectable or metastatic melanoma who no longer respond to other drugs. Nivolumab, a PD-1 inhibitor, is intended for patients who have been previously treated... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS